Fiteni F - Search Results

1

Surrogate end points for overall survival in breast cancer trials: A review.

Fiteni F, Bonnetain F. Fiteni F, et al. Breast. 2016 Oct;29:44-8. doi: 10.1016/j.breast.2016.06.005. Epub 2016 Jul 9. Breast. 2016. PMID: 27400447 Review.

2

Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?

Anota A, Hamidou Z, Paget-Bailly S, Chibaudel B, Bascoul-Mollevi C, Auquier P, Westeel V, Fiteni F, Borg C, Bonnetain F. Anota A, et al. Among authors: fiteni f. Qual Life Res. 2015 Jan;24(1):5-18. doi: 10.1007/s11136-013-0583-6. Epub 2013 Nov 26. Qual Life Res. 2015. PMID: 24277234 Free PMC article.

3

Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: impact of institutions.

Fiteni F, Villanueva C, Bazan F, Perrin S, Chaigneau L, Dobi E, Montcuquet P, Cals L, Meneveau N, Nerich V, Limat S, Pivot X. Fiteni F, et al. Breast. 2014 Apr;23(2):165-9. doi: 10.1016/j.breast.2013.12.003. Epub 2013 Dec 22. Breast. 2014. PMID: 24368024 Free article.

4

Endpoints in cancer clinical trials.

Fiteni F, Westeel V, Pivot X, Borg C, Vernerey D, Bonnetain F. Fiteni F, et al. J Visc Surg. 2014 Feb;151(1):17-22. doi: 10.1016/j.jviscsurg.2013.10.001. Epub 2014 Jan 14. J Visc Surg. 2014. PMID: 24440056 Free article. Review.

5

Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review.

Fiteni F, Nguyen T, Vernerey D, Paillard MJ, Kim S, Demarchi M, Fein F, Borg C, Bonnetain F, Pivot X. Fiteni F, et al. Cancer Med. 2014 Dec;3(6):1502-11. doi: 10.1002/cam4.299. Epub 2014 Aug 11. Cancer Med. 2014. PMID: 25111859 Free PMC article. Review.

6

Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.

Fiteni F, Jary M, Monnien F, Nguyen T, Beohou E, Demarchi M, Dobi E, Fein F, Cleau D, Fratté S, Nerich V, Bonnetain F, Pivot X, Borg C, Kim S. Fiteni F, et al. BMC Gastroenterol. 2014 Aug 13;14:143. doi: 10.1186/1471-230X-14-143. BMC Gastroenterol. 2014. PMID: 25117717 Free PMC article.

7

Fiteni F, Anota A, Westeel V, Bonnetain F. Fiteni F, et al. Bull Cancer. 2015 Apr;102(4):360-6. doi: 10.1016/j.bulcan.2015.02.014. Epub 2015 Mar 21. Bull Cancer. 2015. PMID: 25799875 Review. French.

8

The impact of taxane-based preoperative chemotherapy in gastroesophageal signet ring cell adenocarcinomas.

Kim S, Fiteni F, Paget-Bailly S, Ghiringhelli F, Lakkis Z, Jary M, Fein F, Bonnetain F, Mariette C, Borg C. Kim S, et al. Among authors: fiteni f. J Hematol Oncol. 2015 May 15;8:52. doi: 10.1186/s13045-015-0148-y. J Hematol Oncol. 2015. PMID: 25976888 Free PMC article.

9

Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology.

Fiteni F, Pam A, Anota A, Vernerey D, Paget-Bailly S, Westeel V, Bonnetain F. Fiteni F, et al. Expert Rev Anticancer Ther. 2015;15(8):885-91. doi: 10.1586/14737140.2015.1047768. Epub 2015 May 31. Expert Rev Anticancer Ther. 2015. PMID: 26027598

10

Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients.

Fiteni F, Vernerey D, Bonnetain F, Vaylet F, Sennélart H, Trédaniel J, Moro-Sibilot D, Herman D, Laizé H, Masson P, Derollez M, Clément-Duchêne C, Milleron B, Morin F, Zalcman G, Quoix E, Westeel V. Fiteni F, et al. Eur J Cancer. 2016 Jan;52:120-8. doi: 10.1016/j.ejca.2015.10.004. Epub 2015 Dec 10. Eur J Cancer. 2016. PMID: 26682871 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

47 results

Search Page